The role of tumor necrosis factor in health and disease

Journal of Rheumatology

Volumn 26, Issue SUPPL. 57, 1999, Pages 16-21

  Beutler, Bruce A ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Crohn's disease; Cytokines; Inflammation; Ligand; Rheumatoid arthritis; Tumor necrosis factor

Indexed keywords

LYMPHOTOXIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR;

CELLULAR IMMUNITY; CONFERENCE PAPER; CROHN DISEASE; CYTOKINE RELEASE; HUMAN; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; PRIORITY JOURNAL; RECEPTOR INTRINSIC ACTIVITY; RHEUMATOID ARTHRITIS;

ANIMALS; ARTHRITIS, RHEUMATOID; CROHN DISEASE; HUMANS; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032922359     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (13)

1. Camussi G, Lupia E. The future role of anti-tumour necrosis factor (TNF) products in the treatment of rheumatoid arthritis. Drugs 1998;55:613-20.
2. Bigda J, Holtmann H. TNF receptors - how they function and interact. Arch Immunol Ther Exp (Warsz) 1997;45:263-70.
3. Robak T, Gladalska A. Cytokines in rheumatoid arthritis [in Polish]. Postepy Hig Med Dosw 1997;51:621-36.
4. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440.
5. Barrera P, Boerbooms AM, van de Putte LB, van der Meer JW. Effects of antirheumatic agents on cytokines. Semin Arthritis Rheum 1996;25:234-53.
6. Joyce DA, Steer JH, Abraham LJ. Glucocorticoid modulation of human monocyte/macrophage function: control of TNF-α secretion. Inflamm Res 1997;46:447-51.
7. Wu J, Wilson J, He J, Xiang L, Schur PH, Mountz JD. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest 1996;98:1107-13.
8. Paleolog E. Target effector role of vascular endothelium in the inflammatory response: insights from the clinical trial of anti-TNF-α antibody in rheumatoid arthritis. Mol Pathol 1997;50:225-33.
9. Elliott MJ, Maini RN. Anticytokine therapy in rheumatoid arthritis. Baillieres Clin Rheumatol 1995;9:633-52.
10. Peppel K, Crawford D, Beutler B. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med 1991;174:1483-9.
11. Kolls J, Peppel K, Silva M, Beutler B. Prolonged and effective blockade of tumor necrosis factor activity through adenovirus-mediated gene transfer. Proc Natl Acad Sci USA 1994;91:215-9.
12. Engelmann H, Aderka D, Rubinstein M, Rotman D, Wallach D. A tumor necrosis factor binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 1989;264:11974-80.
13. Wallach D, Boldin M, Goncharov T, et al. Exploring cell death mechanisms by analyzing signaling cascades of the TNF/NGF receptor family. Behring Inst Mitt 1996;97:144-55.